Pre-erythrocytic malaria vaccines: Towards greater efficacy

Nature Reviews Immunology

Volumn 6, Issue 1, 2006, Pages 21-32

  Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIMALARIAL AGENT; BCG VACCINE; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; EXPORTED PROTEIN 1; FANSIDAR; ICC 1132; IMMUNOLOGICAL ADJUVANT; LIPOPEPTIDE; LIVER ANTIGEN; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; PHOSPHORYL LIPID A; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; SPOROZOITE VACCINE; T LYMPHOCYTE ANTIGEN; THROMBOSPONDIN RELATED ADHESION PROTEIN; UNCLASSIFIED DRUG; VIROSOME; WATER OIL CREAM;

CLINICAL TRIAL; DEVELOPMENTAL STAGE; DISEASE SEVERITY; DNA VECTOR; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; ERYTHROCYTE; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; LIFE CYCLE; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VIRUS VECTOR;

ANIMALS; CLINICAL TRIALS, PHASE II; ERYTHROCYTES; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM FALCIPARUM;

EID: 33244471717     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1746     Document Type: Review

References (119)

1. McNeil, D. J. Jr., Malaria vaccine proves effective. New York Times (15 October 2004).
2. Snow, R. W., Guerra, C. A., Noon A. M., Myint, H. Y. & Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Natures 434, 214-217 (2005).
3. Webster, D. P. et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102, 4836-4841 (2005). The first report of sterile protection against malaria with vectored vaccines in a sporozoite-challenge study. One volunteer showed sterile protection that was maintained at 20 months after vaccination and was associated with circulating central memory T cells.
4. Schellenberg, D. et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365, 1481-1483 (2005).
5. World Health Organization. Porfolio of candidate malaria vaccines currently in development. [online], 〈http://www.who.int/vaccine_research/ documents/malaria_table.pdf〉 (2004).
6. Alonso, P. L. et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411-1420 (2004). The first report of clear and significant protection against clinical malaria in African children, using the RTS,S/AS02A vaccine. Protection was observed that lasted several months against both clinical disease and parasitaemia.
7. McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240-1244 (2004).
8. + T cells producing IFN-γ. J. Immunol. 171, 6961-6967 (2003).
9. Vuola, J. M. et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174, 449-455 (2005).
10. + T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nature Med. 10, 406-410 (2004). The first evidence of a peptide-specific strong correlate of protection in a longitudinal field study using a pre-erythrocytic malaria antigen.
11. Richie, T. L. & Saul, A. Progress and challenges for malaria vaccines. Nature 415, 694-701 (2002).
12. Ballou, W. R. et al. Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg. 71, 239-247 (2004).
13. Dunachie, S. J. & Hill, A. V. Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206, 3771-3779 (2003).
14. Moorthy, V. S., Good, M. F. & Hill, A. V. Malaria vaccine developments. Lancet 363, 150-156 (2004).
15. Good, M. F., Stanisic, D., Xu, H., Elliott, S. & Wykes, M. The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol. Rev. 201, 254-267 (2004).
16. Heppner, D. G. Jr et al. Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23, 2243-2250 (2005). A recent account of the longest-running malaria vaccine development programme.
17. Stevenson, M. M. & Riley, E. M. Innate immunity to malaria. Nature Rev. Immunol. 4, 169-180 (2004).
18. Gupta, S. & Day, K. P. A theoretical framework for the immunoepidemiology of Plasmodium falciparum malaria. Parasite-Immunol. 16, 361-370 (1994).
19. Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162 (1967).
20. Clyde, D. F., Most, H., McCarthy, V. C. & Vanderberg, J. P. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266, 169-177 (1973).
21. Bull, P. C. et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Med. 4, 358-360 (1998).
22. Dodoo, D. et al. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun. 69, 3713-3718 (2001).
23. Clark, I. A., al Yaman, F. M. & Jacobson, L. S. The biological basis of malarial disease. Int. J. Parasitol. 27, 1237-1249 (1997).
24. Gardner, M. J. et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
25. Florens, L. et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419, 520-526 (2002).
26. Hall, N. et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science 307, 82-86 (2005).
27. Doolan, D. L. et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl Acad. Sci. USA 100, 9952-9957 (2003).
28. Mueller, A. K. et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl Acad. Sci. USA 102, 3022-3027 (2005).
29. Mueller, A. K., Labaied, M., Kappe, S. H. & Matuschewski, K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167 (2005).
30. Persson, C. et al. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J. Immunol. 169, 6681-6685 (2002).
31. Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336, 86-91 (1997). The initial, highly successful, Phase I/IIa trial of the RTS,S vaccine with various adjuvants.
32. Ballou, W. R. et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1, 1277-1281 (1987).
33. Herrington, D. A. et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257-259 (1987).
34. Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576-1585 (1995).
35. Kester, K. E. et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183, 640-647 (2001).
36. Ballou, W. R. Malaria vaccines in development. Expert Opin. Emerg. Drugs 10, 489-503 (2005).
37. Bojang, K. A. et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927-1934 (2001). Demonstration that the RTS,S vaccine can induce substantial protection against parasitaemia in African adults, but only for 9 weeks.
38. Alloueche, A. et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am. J. Trop. Med. Hyg. 68, 97-101 (2003).
39. H1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180, 1656-1664 (1999). Quantitation of the T-cell immunogenicity of the RTS,S vaccine using IFNγ ELISPOT assays.
40. Stoute, J. A. et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (1998).
41. Birkett, A. et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. 70, 6860-6870 (2002).
42. Walther, M. et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23, 857-864 (2005).
43. + T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31, 1989-1998 (2001).
44. Felnerova, D., Viret, J. F., Gluck, R. & Moser, C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15, 518-529 (2004).
45. Zurbriggen, R. Immunostimulating reconstituted influenza virosomes. Vaccine 21, 921-924 (2003).
46. Moreno, R. et al. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. 2, 838-843 (2001).
47. Mueller, M. S. et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 71, 4749-4758 (2003).
48. + T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664-666 (1987).
49. Doolan, D. L. & Hoffman, S. L. The complexity of protective immunity against liver stage malaria. J. Immunol. 165, 1453-1462 (2000).
50. Romero, P. et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341, 323-326 (1989).
51. + cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect. Immun. 62, 2979-2983 (1994).
52. Hill, A. V. et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360, 434-439 (1992).
53. Allsopp, C. E. et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 26, 1951-1959 (1996).
54. Sedegah, M., Hedstrom, R., Hobart, P. & Hoffman, S. L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl Acad. Sci. USA 91, 9866-9870 (1994).
55. Lanar, D. E. et al. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect. Immun. 64, 1666-1671 (1996).
56. + T cell-mediated protective immunity against malaria. J. Immunol. 158, 1268-1274 (1997).
57. + T-cell-mediated protective immunity against malaria. Proc. Natl Acad. Sci. USA 90, 5214-5218 (1993).
58. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4, 397-402 (1998).
59. Sedegah, M. et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl Acad. Sci. USA 95, 7648-7653 (1998).
60. Gilbert, S. C. et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039-1045 (2002).
61. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime-boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 172, 3094-3100 (2004).
62. Rogers, W. O. et al. Multistage multiantigen heterologous prime-boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect. Immun. 69, 5565-5572 (2001).
63. Rogers, W. O. et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect. Immun. 70, 4329-4335 (2002). Demonstration of the protective efficacy of heterologous prime-boost regimes against simian malaria in macaques.
64. Ockenhouse, C. F. et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177, 1664-1673 (1998).
65. Gilbert, S. C. et al. A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnol. 15, 1280-1284 (1997).
66. McConkey, S. J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Med. 9, 729-735 (2003). Demonstration that strong T-cell responses can be generated by heterologous prime-boost immunization with DNA-MVA regimes in humans, and that these T cells can confer some protection in the absence of antibodies.
67. Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480 (1998). The first report of the immunogenicity of a plasmid DNA prophylactic vaccine in humans.
68. Moorthy, V. S. et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver stage P. falciparum malaria in non-immune volunteers. Vaccine 21, 1995-2002 (2003).
69. Moorthy, V. S. et al. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 188, 1239-1244 (2003).
70. Moorthy, V. et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189, 2213-2219 (2004).
71. Moorthy, V. S. et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1, e33 (2004).
72. Laidlaw, S. M. & Skinner, M. A. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses. J. Gen. Virol. 85, 305-322 (2004).
73. Bejon, P. et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619-626 (2005).
74. Keating, S. M. et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime-boost immunization and correlate with protection against malaria. J. Immunol. 175, 5675-5680 (2005). This study provides evidence that central memory T cells measured by cultured IFNγELISPOT assays correlate better with protection than effector T cells measured by ex vivo IFNγELISPOT assays.
75. Wang, R. et al. Boosting of DNA vaccine-elicited γ-interferon responses in humans by exposure to malaria parasites. Infect. Immun. 73, 2863-2872 (2005).
76. + T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol. 172, 5561-5569 (2004).
77. Reyes-Sandoval, A. et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 78, 7392-7399 (2004).
78. Farina, S. F. et al. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603-11613 (2001).
79. Egan, J. E. et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236, 453-456 (1987).
80. Zavala, F. et al. Synthetic peptide vaccine confers protection against murine malaria. J. Exp. Med. 166, 1591-1596 (1987).
81. Good, M. F. et al. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J. Exp. Med. 164, 655-660 (1986).
82. + T-cell- and γ-interferon- dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoeiii 17-kilodalton hepatocyte erythrocyte protein. Infect. Immun. 67, 5604-5614 (1999).
83. Scheller, L. F. & Azad, A. F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl Acad. Sci. USA 92, 4066-4068 (1995).
84. + T cells. J. Immunol. 171, 2024-2034 (2003).
85. Dolo, A. et al. Epidemiology of malaria in a village of Sudanese savannah in Mali (Bancoumana). Anti-TRAP and anti-CS humoral immunity response. Bull. Soc. Pathol. Exot. 96, 287-290 (2003).
86. Scarselli, E. et al. Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum. Infect. Immun. 61, 3490-3495 (1993).
87. Dolo, A. et al. Thrombospondin related adhesive protein (TRAP), a potential malaria vaccine candidate. Parassitologia 41, 425-428 (1999).
88. John, C. C., Zickafoose, J. S., Sumba, P. O., King, C. L. & Kazura, J. W. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect. Immun. 71, 4320-4325 (2003).
89. Sinigaglia, F. et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336, 778-780 (1988).
90. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004).
91. Flanagan, K. L. et al. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J. Immunol. 167, 4729-4737 (2001).
92. + T cells after clearance of hepatitis C virus. J. Immunol. 169, 2210-2214 (2002).
93. Luty, A. J. et al. Interferon-γ responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 179, 980-988 (1999).
94. John, C. C. et al. γ-Interferon responses to Plasmodium falciparum liver stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect. Immun. 72, 5135-5142 (2004).
95. Ong'echa, J. M. et al. Association of interferon-γ responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. Am. J. Trop. Med. Hyg. 68, 590-597 (2003).
96. Flanagan, K. L. et al. Ex vivo interferon-γ immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am. J. Trop. Med. Hyg. 68, 421-430 (2003).
97. Belkaid, Y. & Rouse, B. T. Natural regulatory T cells in infectious disease. Nature Immunol. 6, 353-360 (2005).
98. + regulatory T cells. Nature Med. 10, 29-30 (2004).
99. Orner, F. M., de Souza, J. B. & Riley, E. M. Differential induction of TGF-β regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J. Immunol. 171, 5430-5436 (2003).
100. + regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 23, 287-296 (2005).
101. + T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J. Immunol. 174, 3344-3351 (2005).
102. Moore, A. C., Gallimore, A., Watkins, K. R., Gilbert, S. C. & Hill, A. V. S. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity to bacterial, viral and parasitic antigens: increased durable cellular immunity with reduced immunodominance. J. Immunol. (in the press).
103. + T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J. Immunol. 174, 3344-3351 (2005).
104. Schwenk, R. et al. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol. 25, 17-25 (2003).
105. Pinder, M. et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS, S/AS02, in semi-immune adults in The Gambia. Clin. Exp. Immunol. 135, 286-293 (2004).
106. Smith, P. G. & Milligan, P. J. Malaria vaccine: 3 or 6 months' protection? Lancet 365, 472-473 (2005).
107. Heppner, D. G. et al. in New Generation Vaccines (eds Levine, M. M., Kaper, J. B., Rappuoli, R., Liu, M. A. & Good, M. F.) 851-860 (Marcel Dekker, New York, 2004).
108. Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618-7628 (2004).
109. Pichyangkul, S. et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1 (42) formulated with novel adjuvants or with alum. Vaccine 22, 3831-3840 (2004).
110. Alonso, P. L. et al. The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet 337, 1499-1502 (1991).
111. Alonso, P. L. et al. A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 6. The impact of the interventions on mortality and morbidity from malaria. Trans. R. Soc. Trop. Med. Hyg. 87 (Suppl. 2), 37-44 (1993).
112. Hill, A. V. et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 352, 595-600 (1991).
113. Gupta, S. & Hill, A. V. Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism. Proc. R. Soc. Lond. B. 261, 271-277 (1995).
114. + type 1 responses in humans by a malaria DNA vaccine. Proc. Natl Acad. Sci. USA 98, 10817-10822 (2001).
115. Doolan, D. L. et al. DNA vaccines for malaria: the past, the present & the future. Indian. J. Med. Res. 106, 109-119 (1997).
116. Luke, T. C. & Hoffman, S. L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206, 3803-3808 (2003).
117. Lawrence, G. et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18, 1925-1931 (2000).
118. Genton, B. et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185, 820-827 (2002).
119. Alonso, P. L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 15 November 2005 (doi:10.1016/S0140-6736(05)67669-6).